Travere Therapeutics, Inc. 8-K

What Happened

• On April 13, 2026 (8-K filed April 14, 2026), Travere Therapeutics announced the U.S. FDA approved FILSPARI® (sparsentan) to reduce proteinuria in adult and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis (FSGS) who do not have nephrotic syndrome. This is the first FDA-approved medicine specifically for FSGS and expands FILSPARI’s label beyond IgA nephropathy (IgAN).
• The approval is supported by the Phase 3 DUPLEX Study (published in the New England Journal of Medicine), a 371-patient trial (ages 8–75) with a double-blind comparison of sparsentan (up to 800 mg) versus irbesartan (up to 300 mg) through Week 108. In DUPLEX, FILSPARI showed statistically significant reductions in proteinuria and a comparable safety profile to irbesartan.

Key Details

• Approval announced April 13, 2026; 8‑K filed April 14, 2026.
• DUPLEX overall result: 46% proteinuria reduction for FILSPARI vs 30% for irbesartan from baseline to Week 108 (nominal p = 0.0299).
• In patients without nephrotic syndrome: 48% proteinuria reduction for FILSPARI vs 27% for irbesartan (nominal p = 0.0075); eGFR treatment difference = +1.1 mL/min/1.73 m2 (mean change to Week 108: -11.3 vs -12.4).
• Travere estimates the U.S. addressable FSGS population without nephrotic syndrome at >30,000 individuals. Safety across adult and pediatric patients was reported as generally well tolerated and comparable to irbesartan.

Why It Matters

• This FDA approval formally adds a second rare kidney disease indication for FILSPARI (beyond IgAN), creating a defined new U.S. patient population the company estimates at more than 30,000.
• DUPLEX clinical data show statistically significant and clinically relevant reductions in proteinuria and a modest eGFR benefit in non‑nephrotic patients, supporting the label expansion.
• The company’s filing also includes standard forward‑looking statements and cautions about risks tied to commercial launch, reimbursement, manufacturing scale-up, and clinical/regulatory uncertainties that investors should consider.